Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

Name: Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC
Uploaded: 2018-02-14T23:50:00.000Z
Description: David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

February 14, 2018

David R. Wise, MD, PhD

Video

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).